

Endothelin-1 Mobilizes Profilin-1–Bound PIP₂ in Cardiac Muscle

NATHAN J. EVANS AND JEFFERY W. WALKER¹

Department of Physiology, University of Wisconsin–Madison, Madison, Wisconsin 53706

Phosphatidylinositol 4,5-bisphosphate (PIP₂) is a key downstream substrate of the endothelin signaling pathway and plays a role in regulating protein function at the membrane-cytoskeletal interface. However, the dynamic properties of distinct pools of PIP₂ are poorly understood, especially for PIP₂ that is bound to cytoskeletal proteins. We investigated the effects of endothelin-1 (ET-1) stimulation on protein-bound PIP₂ in cardiac muscle. Isolated rat myocytes and homogenized mouse ventricles were exposed to 10 nM ET-1 for varying time periods and protein-bound PIP₂ was analyzed using an anti-PIP₂ antibody and Western blotting. Several cytoskeletal proteins were found to contain tightly bound PIP₂, including profilin-1 (~15 kDa), capZ (~32 kDa), gCap39, (~39 kDa) and α -actinin (~106 kDa). Interestingly, ET-1 pretreatment reduced the amount of PIP₂ bound to profilin-1 by 46% after 15 mins, followed by a recovery to near basal levels after 60 mins. ET-1 had no effect on capZ-, gCap39-, or α -actinin-bound PIP₂ levels. To further explore the dynamics of PIP₂ binding, brefeldin-A (BFA) was used to disrupt PIP₂ binding to ADP-ribosylation factors and to impair receptor internalization. Pretreatment with 1 μ M BFA increased the PIP₂ signal on profilin-1 \times 54% after 15 mins, followed by a decline to subbasal levels after 60 mins. Like ET-1, BFA had no effect on levels of PIP₂ bound to capZ or to α -actinin. Taken together, the data indicate that profilin-1 binds PIP₂ dynamically and may serve as a key regulator of the balance between cytoskeletal integrity and PIP₂ availability for Ca²⁺/PKC signaling in the heart. *Exp Biol Med* 231:882–887, 2006

Key words: brefeldin-A; α -actinin; phosphoinositides

Introduction

Phosphatidylinositol 4,5-bisphosphate (PIP₂) plays multiple roles in a variety of signaling pathways, as well

as modulating numerous actin regulatory proteins (1). As an intermediate in the endothelin pathway, PIP₂ is hydrolyzed by phospholipase C (PLC) into the second messengers diacylglycerol and inositol 1,4,5 trisphosphate. Depletion of PIP₂ caused by G_{αq} overexpression in transgenic mice has been shown to increase cardiomyocyte apoptosis and contribute to subsequent heart failure (2). Hamsters suffering from severe cardiomyopathy and congestive heart failure have reduced PIP₂ mass in the sarcolemma, which is thought to jeopardize cardiac function (3). In addition, depletion of PIP₂ has been shown to increase delayed rectifier K⁺ currents in atrial myocytes (4). Therefore, regulation of PIP₂ levels appears to be a critical element for proper cardiac function.

PIP₂ has been implicated as a possible membrane-anchoring site for ADP-ribosylation factors (ARFs), a family of small GTP-binding proteins that regulate membrane traffic (5). ARFs can interact with membrane-bound PIP₂, followed by insertion of its N-terminus into the hydrophobic region of the membrane bilayer. PIP₂ may influence the accessibility of ARFs to the catalytic domain of guanine nucleotide exchange factors (GEFs; Ref. 5), or activate a variety of GTPase-activating proteins, which provide additional membrane trafficking regulation (6). Inhibition of ARFs/GEFs with brefeldin A (BFA) would be expected to increase the availability of PIP₂ for other purposes.

Another possible regulator of the PIP₂ pool is the ~15 kDa cytoskeletal protein profilin. Profilin is an actin-binding protein that is essential in actin polymerization, but also binds polyphosphoinositol lipids (7). Three separate profilin proteins have been identified and characterized, though only profilin-1 is present in cardiac tissue. Profilin has also been linked to membrane trafficking, as noted by its presence at budding Golgi vesicles and its recruitment of dynamin 2, a protein necessary for vesicle budding (8).

In this study we examined the dynamic nature of PIP₂ pools bound to cytoskeletal proteins in the heart. Endothelin-1 was added for G-protein stimulated PLC breakdown of PIP₂. BFA, a macrocyclic lactone synthesized by fungi and an inhibitor of ARF/GEFs, was used to elevate PIP₂ levels as well as to inhibit membrane trafficking (9). Our evidence shows the unique ability of profilin-1 to bind PIP₂ dynamically and suggests roles in regulating the availability

This work was supported by grant RO1HL081386 from the National Institutes of Health.

¹ To whom correspondence should be addressed at Department of Physiology, University of Wisconsin, 1300 University Avenue, Madison, WI 53706. E-mail: jwalker@physiology.wisc.edu

Received September 29, 2005.
Accepted November 17, 2005.

1535-3702/06/2316-0882\$15.00
Copyright © 2006 by the Society for Experimental Biology and Medicine

of PIP₂ for second messenger production and in mediating endothelin-induced cytoskeletal reorganization in the heart.

Materials and Methods

Materials. Reagents were obtained from Sigma Chemical Company (St. Louis, MO), unless otherwise stated. Tris-base and glycine were obtained from Fisher Scientific (Fair Lawn, NJ). Collagenase was from Worthington Enzymes (Freehold, NJ).

Sample preparation. Ventricular myocytes were isolated by enzymatic digestion from 3-month-old male Sprague-Dawley rats using collagenase and hyaluronidase, as described previously (10, 11). Animal handling practices used in this study have been reviewed by and received approval from the Animal Care Committee of the University of Wisconsin. Myocytes were maintained in Ca²⁺ Ringer's solution (in mM: 125, NaCl; 5, KCl; 25, HEPES; 2, NaH₂PO₄; 1.2, MgSO₄; 5, pyruvate; 11, glucose; 0.5, CaCl₂; 20, taurine; pH 7.4). Ventricular tissue from wild-type 6- to 8-week-old mice was homogenized and maintained in Ca²⁺ Ringer's solution. Isolated rat myocytes and homogenized mouse tissue were exposed to 10 nM endothelin-1 (ET-1), 1 μ M BFA, or both for varying time periods and then skinned using 0.5% Triton X-100. Samples were then washed, centrifuged, and resuspended in Ca²⁺ Ringer's solution or relax buffer (see below).

Western blotting. Approximately 2 mg total protein was run on a 12% sodium dodecyl sulfate (SDS)-polyacrylamide gel and transferred to polyvinylidene fluoride membranes. PIP₂-binding proteins and profilin-1 were targeted using immunoblot analyses with a monoclonal anti-PIP₂ antibody and a polyclonal antiprofilin antibody from Novus Biologicals (Littleton, CO). α -actinin was detected with a monoclonal antibody from Sigma.

Confocal microscopy. Ventricular myocytes were isolated as described previously (10, 11) and maintained in relax buffer (in mM: 5, ATP; 100, KCl; 10, imidazole; 1, MgCl₂; 2, ethylene glycol tetraacetic acid; 1, phenyl-methylsulfonyl fluoride; 1, benzamidine; 1, dithiothreitol; 20, 2,3 butanedione monoxime; and 1, protease inhibitor cocktail tablet; pH 7.0), followed by skinning in 100 μ g/ml saponin. Samples were transferred to relax buffer containing 2% BSA for blocking and incubated with a monoclonal anti-profilin-1 antibody, then with an Alexa Fluor 568 secondary antibody from Molecular Probes (Eugene, OR). Imaging was performed with a Bio-Rad MRC 1024 laser scanning confocal microscope equipped with a mixed gas (Ar/Kr) laser operated by 24-bit Laser-Sharp software (Carl Zeiss, Thornwood, NY).

Results

Western blot analyses were used to determine the presence of PIP₂-binding proteins in cardiac muscle tissue. Primary antibody to PIP₂ detected multiple protein bands in both isolated rat ventricular myocytes and homogenized

mouse ventricular tissue (Fig. 1). Four of the proteins were tentatively identified as α -actinin (~106 kDa), gCap39 (~39 kDa), capZ (~32 kDa), and profilin-1 (~15 kDa) on the basis of their mobility in SDS-PAGE (Fig. 1), peptide mass fingerprinting (not shown), and Western blots (below). All four proteins are known to be expressed in cardiac muscle and are thought to bind PIP₂ (7, 8, 12–14).

To investigate the dynamic nature of cytoskeletal and membrane-bound PIP₂ pools, ET-1 was added to perturb the distribution via PLC breakdown of membrane-bound PIP₂. Exposure to 10 nM ET-1 had a pronounced effect on profilin-1-bound PIP₂ after 15 mins (Fig. 1), significantly reducing PIP₂ levels by 46% compared with control samples (Fig. 2). PIP₂ levels returned to near basal levels after 60 mins of ET-1 exposure (Figs. 1 and 2). Conversely, ET-1 had no effect on α -actinin-, gCap39- or capZ-bound PIP₂ (Fig. 1). Therefore, for all subsequent quantitative analyses, profilin-1-bound PIP₂ was normalized to α -actinin-bound PIP₂ within the same lane to serve as an internal reference. This observation suggests that profilin-1 may have a role in maintaining consistent availability of PIP₂ for ET-1 signal transduction.

The pharmacologic agent BFA was used to inhibit GEFs, thereby inhibiting GTP for GDP exchange and subsequent ARF activation. In myocytes and ventricular tissue exposed to 1 μ M BFA, a 54% increase in profilin-1-bound PIP₂ was noted after 15 mins, followed by a decline to subbasal levels after 60 mins (Fig. 2). Similar to the results seen with ET-1 alone, BFA had no effect on α -actinin-, gCap39-, or capZ-bound PIP₂ (not shown). Again, profilin-1-bound PIP₂ was normalized to α -actinin-bound PIP₂ within the same lane to serve as an internal reference.

Exposure of myocytes and ventricular tissue to combined treatment with 10 nM ET-1 and 1 μ M BFA




Figure 1. ET-1 affects profilin-1-bound PIP₂, but not α -actinin, gCap39, or capZ. Mouse ventricular tissue was exposed to 10 nM ET-1 and skinned in 0.5% Triton X-100. Samples were blotted with an anti-PIP₂ antibody over a 60-min time course. (A) α -Actinin. (B) gCap39 and capZ (the faint band at ~27 kDa was not identified). (C) Profilin-1.




Figure 2. Effects of ET-1, BFA, and combined treatment with ET-1 and BFA on profilin-1-bound PIP₂. Ventricular tissue was exposed to 10 nM ET-1, 1 μM BFA, or both for various time periods and skinned in 0.5% Triton X-100. (Upper) Representative blots of mouse ventricular tissue using an anti-PIP₂ antibody. (Lower) Graph summarizes profilin-1-bound PIP₂ band densities standardized to α-actinin-bound PIP₂ and graphed over a 60-min time course. Data from rat and mouse tissues were combined. *1 μM BFA results in a 54% increase in profilin-1-bound PIP₂ after 15 mins, *P* < 0.05. **10 nM ET-1 results in a 46% reduction in profilin-1-bound PIP₂ after 15 mins, *P* < 0.05.

resulted in a reduction in profilin-1-bound PIP₂ similar to ET-1 exposure alone after 15 mins. However, the rise in PIP₂ levels to near-basal levels after 60 mins was no longer observed. Instead, treatment with ET-1 and BFA resulted in a continuous drop in profilin-1-bound PIP₂ throughout the 60-min duration (Fig. 2). Again, the combined treatment had no effect on α-actinin-, gCap39- or capZ-bound PIP₂ (not shown). Combined treatment of 1 μM BFA and 10 nM ET-1 eliminated the transient increase in profilin-1-bound PIP₂ seen with BFA exposure alone (Fig. 2). One possibility for this response could stem from BFA inhibition of an endothelin receptor internalization pathway, leading to sustained PLC activation and PIP₂ hydrolysis. In support of this interpretation, pretreatment of cardiac myocytes with

hypertonic sucrose to block clathrin-dependent receptor internalization also inhibited recovery of profilin-1-bound PIP₂ levels at 60 mins (not shown).

Next, we focused our attention on localizing profilin-1 in cardiac muscle using saponin-skinned rat ventricular myocytes. Localization experiments using confocal images with an anti-profilin-1 antibody resulted in a distinct striated pattern (Fig. 3A). This demonstrated that profilin-1 binds with a periodicity similar to that of the transverse tubules and could be strongly associated with the cardiac transverse tubule and/or Z-line. Secondary antibody alone resulted in only faint binding throughout the myocytes (Fig. 3B). Further work was carried out to localize the PIP₂ signal in saponin-skinned rat ventricular myocytes and mouse




Figure 3. Localization of profilin-1 in rat ventricular myocytes. (A) Myocytes were skinned in 100 μ g/ml saponin, incubated with an anti-profilin-1 antibody, then with an Alexa Fluor 568 secondary. (B) Myocytes were skinned in 100 μ g/ml saponin and incubated in secondary antibody only. Bar, 10 μ m.

ventricular tissue. Using the same anti-PIP₂ antibody, PIP₂ was found to have a similar transverse tubule or Z-line periodicity (not shown). Secondary antibody alone again resulted in only diffuse binding throughout the myocytes.

To dispel the possibility that the observed changes in PIP₂ levels on blots were dependent upon protein up- or downregulation or loading error, Western blotting analysis with an anti- α -actinin antibody or an anti-profilin-1 antibody was performed. Blots demonstrated protein stability and an equivalent protein load in all sample lanes, as indicated by similar band densities at 106 kDa for α -actinin and 15 kDa for profilin-1 (Fig. 4). Thus, ET-1 treatment for up to 60 mins did not stimulate profilin-1 upregulation or protein degradation, but affected the level of PIP₂ bound to profilin-1.

Discussion

This study provides evidence for dynamic binding of PIP₂ to a cytoskeletal protein in cardiac tissue. Specifically, we showed that treatment of rat ventricular myocytes or mouse ventricular tissue with either the G-protein coupled receptor ligand ET-1 or the ARF/GEF inhibitor BFA reversibly altered the amount of PIP₂ bound to profilin-1. The results suggest a potential role for profilin-1 in regulating the availability of PIP₂ as a substrate for endothelin-stimulated PLC. Profilin-1-bound PIP₂ is also likely to play an important role in maintaining cytoskeletal integrity at the transverse tubule/Z-line interface, and in its regulation by endothelin. A recent study in adipocytes reported regulation of insulin stimulated GLUT4 translocation by endothelin via a PIP₂- and actin-dependent

mechanism (15), although the role of profilin-1 was not examined.

Importantly, profilin-1 alone displayed this unique ability to regulate PIP₂ levels in cardiac tissue as compared with other known PIP₂-binding cytoskeletal proteins including α -actinin, gCap39, and capZ. We suggest that profilin-1 plays a homeostatic role in maintaining membrane-bound PIP₂ levels at a consistent level, which may be essential for proper endothelin-induced signal transduction. Maintenance of PIP₂ levels appears to be required for normal cardiac function, as indicated by studies that show a link between PIP₂ depletion and cardiomyopathy (1–3). Such a mechanism also provides a possible link between GPCR-mediated PIP₂ turnover and reorganization of the profilin-regulated actin cytoskeleton.

Another finding of this study suggests a possible relationship between endothelin receptor function, membrane trafficking, and PIP₂ levels. When ET-1 is added to myocytes, our results suggest that membrane-bound PIP₂ is transiently depleted, followed by its replenishment (buffering) by profilin-1-bound PIP₂. This would account for the initial drop in profilin-1-bound PIP₂. The ensuing recovery over 60 mins is presumably because of desensitization and/or internalization of ET-1 receptors and resynthesis of PIP₂. When ET-1 was combined with BFA, profilin-1-bound PIP₂ dropped continuously over 60 mins with no recovery. One possibility is that BFA inhibited receptor desensitization and/or internalization and experiments with hypertonic sucrose reinforced this interpretation. With the endothelin receptor in a constantly “turned-on” state, membrane PIP₂ levels would be dramatically depleted, as would profilin-1-bound PIP₂.




Figure 4. α -Actinin and profilin-1 protein signals. Samples were blotted with an anti- α -actinin antibody or an anti-profilin-1 antibody and resultant band densities were graphed over a 60-min time course. (Upper) Representative blots and (lower) graph summarizing results of three separate experiments. The lane labeled with (+) refers to a profilin-1 marker.

Elucidating the precise mechanism of BFA's action on ET-1 receptor function will require further investigation.

Further evidence for buffering of PIP_2 levels by profilin-1 was obtained using BFA treatment alone. The addition of BFA (in the absence of ET-1) would be expected to prevent PIP_2 binding to ARFs and consequently generate a surplus of PIP_2 in the membrane pool. Such a surplus could then drive PIP_2 onto its cytoskeletal buffer profilin-1, albeit only transiently as observed here.

In conclusion, we have provided evidence that the actin-binding protein profilin-1 is an important PIP_2 -binding protein in cardiac muscle tissues. In contrast to the PIP_2 bound to other cardiac cytoskeletal proteins such as α -actinin, gCap39, and capZ, the pool of PIP_2 bound to profilin-1 was depleted by ET-1 stimulation and was enhanced by treatment with BFA. Profilin-1 protein was also localized in this study to cardiac T-tubules or Z-lines where it would be in or near the same membrane

compartment as ET receptors. The data indicate that profilin-1 may participate in the dual roles of regulating availability of PIP₂ for ET signaling and mediating GPCR control of the actin cytoskeleton.

1. Yamamoto M, Hilgemann DH, Feng S, Bito H, Ishihara H, Shibasaki Y, Yin HL. Phosphatidylinositol 4,5-bisphosphate induces actin stress-fiber formation and inhibits membrane ruffling in CV1 cells. *J Cell Biol* 152:867–876, 2001.
2. Howes AL, Arthur JF, Zhang T, Miyamoto S, Adams JW, Dorn II GW, Woodcock EA, Brown JH. Akt-mediated cardiomyocyte survival pathways are compromised by G alpha q-induced phosphoinositide 4,5-bisphosphate depletion. *J Biol Chem* 278:40343–40351, 2003.
3. Ziegelhoffer A, Tappia PS, Mesaali N, Sahi N, Dhalla NS, Panagia V. Low level of sarcolemmal phosphatidylinositol 4,5-bisphosphate in cardiomyopathic hamster (UM-X7.1) heart. *Cardiovasc Res* 49:118–126, 2001.
4. Ding WG, Toyoda F, Matsuura H. Regulation of cardiac IKs potassium current by membrane phosphatidylinositol 4,5-bisphosphate. *J Biol Chem* 279:50726–50734, 2004.
5. Roth MG. Lipid regulators of membrane traffic through the Golgi complex. *Trends Cell Biol* 9:174–179, 1999.
6. Randazzo PA. Resolution of two ADP-ribosylation factor 1 GTPase-activating proteins from rat liver. *Biochem J* 324:413–419, 1997.
7. Chaudhary A, Chen J, Gu QM, Witke W, Kwiatkowski DJ, Prestwich GD. Probing the phosphoinositide 4,5-bisphosphate binding site of human profilin 1. *Chem Biol* 5:273–281, 1998.
8. Witke W. The role of profilin complexes in cell motility and other cellular processes. *Trends Cell Biol* 14:461–469, 2004.
9. Klausner RD, Donaldson JG, Lippincott-Schwartz J, Brefeldin A: insights into the control of membrane traffic and organelle structure. *J Cell Biol* 116:1071–1080, 1992.
10. Huang X, Pi Y, Lokuta A, Greaser M, Walker J. Arachidonic acid stimulates PKC- ϵ redistribution in heart cells. *J Cell Sci* 110:1625–1634, 1997.
11. Pi Y, Walker J. Diacylglycerol and fatty acids synergistically increase cardiomyocyte contraction via activation of PKC. *Am J Physiol* 279: H26–H34, 2000.
12. Fukami K, Endo T, Imamura M, Takenawa T. α -Actinin and vinculin are PIP₂ binding proteins involved in signaling by tyrosine kinase. *J Biol Chem* 269:1518–1522 1994.
13. Schafer DA, Jennings PB, Cooper JA. Dynamics of capping protein and actin assembly in vitro: uncapping barbed ends by polyphosphoinositides. *J Cell Biol* 135:169–179, 1996.
14. Almenar-Queralt A, Gregorio CC, Fowler VM. Tropomodulin assembles early in myofibrillogenesis in chick skeletal muscle: evidence that thin filaments rearrange to form striated myofibrils. *J Cell Sci* 112:1111–1123, 1999.
15. Strawbridge AB, Elmendorf JS. Phosphatidylinositol 4,5-bisphosphate reverses endothelin-1-induced insulin resistance via an actin-dependent mechanism. *Diabetes* 54:1698–1705, 2005.